Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE219276 | GEO | 2022/12/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion [RNA-seq]

Project description:Our preliminary data found that TNBC cells with Chrom 17p loss are more resistant to chemotherapy drug treatment, compare to cell with 17p intact.To investigate the role of cancer stemness, weg performed this gene expression profiling analysis

2022-12-10 | GSE219274 | GEO

Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion [scRNA-seq]

2022-12-10 | GSE219275 | GEO

Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion

Project description:Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion

| PRJNA907837 | ENA

Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion [RNA-seq]

Project description:Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion [RNA-seq]

| PRJNA907844 | ENA

Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion [scRNA-seq]

Project description:Effect of Doxorubicin on gene expression of HS578T cells with or without heterozygous chromosomal 17p deletion [scRNA-seq]

| PRJNA907843 | ENA

Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.

Project description:Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic events in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding the catalytic subunit of RNA polymerase II (RNAP2) is also included in a ~20-megabase deletion region of 17p in 63% of metastatic castration-resistant prostate cancer (CRPC). Using a focused CRISPR-Cas9 screen, we discovered that heterozygous loss of 17p confers a selective dependence of CRPC cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates POLR2A by the K63-linked ubiquitination and thus elevates the RNAP2-mediated mRNA synthesis. Combined inhibition of RNAP2 and RBX1 profoundly suppress the growth of CRPC in a synergistic manner, which potentiates the therapeutic effectivity of the RNAP2 inhibitor, α-amanitin-based antibody drug conjugate (ADC). Given the limited therapeutic options for CRPC, our findings identify RBX1 as a potentially therapeutic target for treating human CRPC harboring heterozygous deletion of 17p.

| S-EPMC6197287 | biostudies-literature

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.

Project description:Ibrutinib is a novel oral therapy that has shown significant efficacy as initial treatment of chronic lymphocytic leukemia (CLL). It is a high-cost continuous therapy differing from other regimens that are given for much shorter courses. Our objective was to evaluate the cost-effectiveness of ibrutinib for first-line treatment of CLL in patients older than age 65 years without a 17p deletion. We developed a semi-Markov model to analyze the cost-effectiveness of ibrutinib vs a comparator therapy from a US Medicare perspective. No direct comparison between ibrutinib and the best available treatment alternative, obinutuzumab plus chlorambucil (chemoimmunotherapy), exists. Therefore, we compared ibrutinib to a theoretical treatment alternative, which was modeled to confer the effectiveness of an inferior treatment (chlorambucil alone) and the costs and adverse events of chemoimmunotherapy, which would provide ibrutinib with the best chance of being cost-effective. Even so, the incremental cost-effectiveness ratio of ibrutinib vs the modeled comparator was $189?000 per quality-adjusted life-year (QALY) gained. To reach a willingness-to-pay threshold (WTP) of $150?000 per QALY, the monthly cost of ibrutinib would have to be at most $6800, $1700 less than the modeled cost of $8500 per month (a reduction of $20?400 per year). When the comparator efficacy is increased to more closely match that seen in trials evaluating chemoimmunotherapy, ibrutinib costs more than $262?000 per QALY gained, and the monthly cost of ibrutinib would need to be lowered to less than $5000 per month to be cost-effective. Ibrutinib is not cost-effective as initial therapy at a WTP threshold of $150?000 per QALY gained.

| S-EPMC6093732 | biostudies-literature

An Epigenetic Mechanism Underlying Chromosome 17p Deletion-Driven Tumorigenesis.

Project description:Chromosome copy-number variations are a hallmark of cancer. Among them, the prevalent chromosome 17p deletions are associated with poor prognosis and can promote tumorigenesis more than TP53 loss. Here, we use multiple functional genetic strategies and identify a new 17p tumor suppressor gene (TSG), plant homeodomain finger protein 23 (PHF23). Its deficiency impairs B-cell differentiation and promotes immature B-lymphoblastic malignancy. Mechanistically, we demonstrate that PHF23, an H3K4me3 reader, directly binds the SIN3-HDAC complex through its N-terminus and represses its deacetylation activity on H3K27ac. Thus, the PHF23-SIN3-HDAC (PSH) complex coordinates these two major active histone markers for the activation of downstream TSGs and differentiation-related genes. Furthermore, dysregulation of the PSH complex is essential for the development and maintenance of PHF23-deficient and 17p-deleted tumors. Hence, our study reveals a novel epigenetic regulatory mechanism that contributes to the pathology of 17p-deleted cancers and suggests a susceptibility in this disease. SIGNIFICANCE: We identify PHF23, encoding an H3K4me3 reader, as a new TSG on chromosome 17p, which is frequently deleted in human cancers. Mechanistically, PHF23 forms a previously unreported histone-modifying complex, the PSH complex, which regulates gene activation through a synergistic link between H3K4me3 and H3K27ac.This article is highlighted in the In This Issue feature, p. 1.

| S-EPMC8591992 | biostudies-literature

PATZ1 is a DNA damage responsive transcription factor that inhibits p53 function [with and without doxorubicin treatment]

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-07-30 | E-GEOD-71558 | biostudies-arrayexpress

Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-05-01 | GSE116132 | GEO